SeaStar MEdical Holdings Publishes Manuscript On Multiorgan Failure Patients Treated With Selective Cytopheretic Device
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holdings has published a manuscript in Transplantation Direct detailing the positive impact of its Selective Cytopheretic Device (SCD) on critically ill pediatric and adult patients with multiorgan failure.
May 22, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SeaStar Medical Holdings' publication in Transplantation Direct highlights the effectiveness of its Selective Cytopheretic Device (SCD) in treating critically ill patients with multiorgan failure, which could positively impact the company's stock price.
The publication of positive clinical results in a reputable journal can enhance investor confidence in SeaStar Medical Holdings' product, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100